THE DEAL, AT A GLANCE
From the announcementCambridge spinout T-Therapeutics
Who is involvedBacked by Advent Life Sciences, British Business Bank, Inc, University of CambridgeFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedCambridge spinout T-Therapeutics raised $133M Series B, announced 2026-11-05From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersCambridge spinout T-Therapeutics raised a $133M Series B for TCR bispecifics, placing the round at the 81th percentile by size among tracked Unclassified rounds.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Cambridge spinout T-Therapeutics · Financing Record
Explore source-linked visual explanations for Cambridge spinout T-Therapeutics. Unsupported claims are withheld while source review continues.
Record 15436 · Recorded date: 2026-11-05
Explore company records →